<DOC>
	<DOCNO>NCT00020969</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : - Determine percentage patient low-risk myelodysplastic syndrome ( MDS ) achieve major hematologic improvement treatment arsenic trioxide . - Determine percentage patient high-risk MDS achieve complete partial remission major hematological improvement treatment drug . - Determine durability responses patient treated drug . - Determine duration overall progression-free survival patient treated drug . - Assess quality life patient treated drug . - Assess toxicity profile drug patient . OUTLINE : This multicenter study . Patients stratify accord risk score ( low risk v high risk ) . Patients receive arsenic trioxide IV 5 day week week 1-2 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . Patients stable disease well may receive additional course treatment . Patients achieve complete remission ( CR ) receive 2 additional course treatment documentation CR . Quality life assess baseline , every 8 week study , 4 week study completion . Patients follow 4 week , every 3 month completion study treatment , annually thereafter . PROJECTED ACCRUAL : A total 30-110 patient ( 15-55 per stratum ) accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis myelodysplastic syndrome ( MDS ) Refractory anemia ( RA ) RA ring sideroblast RA excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia Lowrisk MDS patient : If serum erythropoietin le 200 IU/mL , must fail prior recombinant epoetin alfa ( EPO ) trial No prior acute myeloid leukemia PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : More 3 month Hematopoietic : Not specify Hepatic : Bilirubin great 2.5 time upper limit normal ( ULN ) SGPT SGOT great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : Absolute QT interval le 460 msec presence magnesium great 1.8 mg/dL potassium great 4.0 mEq/L Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 30 day since prior biologic therapy ( except recombinant EPO lowrisk MDS patient ) Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : At least 30 day since prior radiotherapy Surgery : Not specify Other : At least 30 day since prior cytotoxic agent At least 30 day since prior investigational agent No prior arsenic trioxide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
</DOC>